Market revenue in 2023 | USD 32.3 million |
Market revenue in 2030 | USD 101.9 million |
Growth rate | 17.8% (CAGR from 2023 to 2030) |
Largest segment | (crispr)/cas9 |
Fastest growing segment | (CRISPR)/Cas9 |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease |
Key market players worldwide | Merck KGaA, Cibus Inc Ordinary Shares - Class A, Recombinetics, Sangamo Therapeutics Inc, Editas Medicine Inc, Precision BioSciences Inc, CRISPR Therapeutics AG, Intellia Therapeutics Inc, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, AstraZeneca PLC, Takara Bio Inc, Horizon Discovery, Danaher Corp, Genscript Biotech Corp Class H, New England Biolabs, Origene Technologies, Bluebird bio Inc, Lonza Group Ltd, Thermo Fisher Scientific Inc |
(crispr)/cas9 was the largest segment with a revenue share of 47.37% in 2023. Horizon Databook has segmented the Thailand genome editing market based on (crispr)/cas9, talens/megatals, zfn, meganuclease covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing investments by the Thai government, along with the growing market, are responsible for the country becoming a hub for precision medicine and genomic projects. Some of the projects undertaken by the Thailand government are Genomics Thailand Initiative launched in 2019, National Biobank of Thailand (NBT) established in 2019, and the Southeast Asian genome-sequencing project.
Over the past few years, the CDC and Ministry of Public Health in Thailand have been working on developing intervention strategies to fight against high-risk diseases. The prevalence of cancer has increased in the country, accounting for 19% of the overall deaths, followed by 12% of deaths due to ischemic heart disease and 10% due to stroke.
Moreover, an increase in the incidence of infectious diseases such as hepatitis, diarrhea, dengue fever, malaria, Japanese encephalitis, HIV, leptospirosis, and rabies is expected to fuel the demand for genome editing technologies for proper diagnosis & treatment development.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account